Frequency of difficult-to-manage and treatment-refractory axial SpA: insights from the German RABBIT-SpA register using recent ASAS definitions
Applying the ASAS definitions in a large real-world cohort identified clinically relevant subgroups with D2M and TR. These findings support their clinical utility and highlight the need for phenotype-specific management strategies.
Authors
- Denis Poddubnyy (ORCID: https://orcid.org/0000-0002-4537-6015)
- Anja Weiß (ORCID: https://orcid.org/0000-0003-2069-2190)
- Fabian Proft (ORCID: https://orcid.org/0000-0003-4306-033X)
- Xenofon Baraliakos (ORCID: https://orcid.org/0000-0002-9475-9362)
- Anne C. Regierer (ORCID: https://orcid.org/0000-0003-2456-4049)
- Stephanie Lembke (ORCID: https://orcid.org/0000-0003-0426-0312)
- H Kellner
Institutions
- University Health Network (CA)
- Humboldt-Universität zu Berlin (DE)
- Rheumazentrum Ruhrgebiet (DE)
- German Rheumatism Research Centre (DE)
- Center for Rheumatology (US)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1093/rheumatology/keaf641
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Biogen
- Celgene
- Celltrion
- Cilag